{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:35:27Z","timestamp":1792197327109,"version":"4.4.0"},"reference-count":289,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Oncolytic virotherapy (OVT) has emerged as a promising and innovative cancer treatment strategy that harnesses engineered viruses to selectively infect, replicate within, and destroys malignant cells while sparing healthy tissues. Beyond direct oncolysis, oncolytic viruses (OVs) exploit tumor-specific metabolic, antiviral, and immunological vulnerabilities to reshape the tumor microenvironment (TME) and initiate systemic antitumor immunity. Despite promising results from preclinical and clinical studies, several barriers, including inefficient intratumoral virus delivery, immune clearance, and tumor heterogeneity, continue to limit the therapeutic advantages of OVT as a standalone modality and hindered its clinical success. Recent advances in OV engineering have enhanced viral tropism, immune evasion, and transgene delivery, enabling better tumor targeting and penetration and sustained immune activation in malignant tumors. Moreover, rational combination strategies with immune checkpoint inhibitors (ICIs), chemotherapeutics, and immunometabolic modulators are reshaping OVT into a versatile strategy for precision oncology. This review highlights the mechanistic innovations driving next-generation OV engineering, explores emerging combination regimens, and discusses future directions to overcome resistance and maximize clinical efficacy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1618751","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T05:26:40Z","timestamp":1756099600000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer\u2019s defenses"],"prefix":"10.3389","volume":"16","author":[{"given":"Tolulope O.","family":"Omolekan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy T.","family":"Folahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulu Z.","family":"Tesfay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harikrishnan","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ojasvi","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Rahimian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khandoker Usran","family":"Ferdous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Ghavimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Cios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy K.","family":"Beng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oswald","family":"D'Auvergne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh J.","family":"Borad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin G.","family":"Kousoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"DiGiuseppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolni Marius","family":"Nagalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Christopher","family":"Chamcheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.08.007","article-title":"Oncolytic virus with attributes of vesicular stomatitis virus and measles virus in hepatobiliary and pancreatic cancers","volume":"18","author":"Nagalo","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5501\/wjv.v10.i5.229","article-title":"Oncolytic virus therapy in cancer: A current review","volume":"10","author":"Santos Apolonio","year":"2021","journal-title":"World J Virol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040588","article-title":"Oncolytic virotherapy in solid tumors: the challenges and achievements","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2021.110750","article-title":"Restructuring the ONYX-015 adenovirus by using spike protein genes from SARS-CoV-2 and MERS-CoV: Possible implications in breast cancer treatment","volume":"159","author":"Parmar","year":"2022","journal-title":"Med Hypotheses"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/OV.S100072","article-title":"Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma","volume":"6","author":"Babiker","year":"2017","journal-title":"Oncolytic Virother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt130","article-title":"Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer","volume":"105","author":"Poirier","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"B7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41419-020-2236-3","article-title":"Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer","volume":"11","author":"Ma","year":"2020","journal-title":"Cell Death Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2667","article-title":"Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13046-016-0353-8","article-title":"Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model","volume":"35","author":"El-Shemi","year":"2016","journal-title":"J Exp Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2016.32","article-title":"Retargeted adenoviruses for radiation-guided gene delivery","volume":"23","author":"Kaliberov","year":"2016","journal-title":"Cancer Gene Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1186\/s12967-023-04709-z","article-title":"Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages","volume":"21","author":"Shen","year":"2023","journal-title":"J Transl Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1021\/acs.nanolett.9b00145","article-title":"Genetically engineered cell membrane nanovesicles for oncolytic adenovirus delivery: a versatile platform for cancer virotherapy","volume":"19","author":"Lv","year":"2019","journal-title":"Nano Lett"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-02118-7","article-title":"An oncolytic virus-T cell chimera for cancer immunotherapy","volume":"42","author":"Chen","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200913","article-title":"Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade","volume":"32","author":"Tesfay","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2217\/epi.15.16","article-title":"Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy","volume":"7","author":"Park","year":"2015","journal-title":"Epigenomics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1158133","article-title":"PI3K\/Akt\/Nrf2 mediated cellular signaling and virus-host interactions: latest updates on the potential therapeutic management of SARS-CoV-2 infection","volume":"10","author":"Lekshmi","year":"2023","journal-title":"Front Mol Biosci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11122377","article-title":"Nrf2 Regulates Oxidative Stress and Its Role in Cerebral Ischemic Stroke","volume":"11","author":"Wang","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"9103","DOI":"10.1038\/s41598-021-88478-z","article-title":"(-)-Epigallocatechin-3-gallate induces apoptosis and differentiation in leukaemia by targeting reactive oxygen species and PIN1","volume":"11","author":"Della Via","year":"2021","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/nu10111755","article-title":"Sulforaphane from cruciferous vegetables: recent advances to improve glioblastoma treatment","volume":"10","author":"Sita","year":"2018","journal-title":"Nutrients"},{"key":"B20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1186\/s12885-020-07256-8","article-title":"Clinical effects of curcumin in enhancing cancer therapy: A systematic review","volume":"20","author":"Mansouri","year":"2020","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.immuni.2019.07.003","article-title":"Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance","volume":"51","author":"Rivadeneira","year":"2019","journal-title":"Immunity"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e009768","DOI":"10.1136\/jitc-2024-009768","article-title":"Mitochondrial metabolic reprogramming of macrophages and T cells enhances CD47 antibody-engineered oncolytic virus antitumor immunity","volume":"12","author":"Zhao","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12967-023-04017-6","article-title":"Immunogenic cell death in cancer: concept and therapeutic implications","volume":"21","author":"Galluzzi","year":"2023","journal-title":"J Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2165","article-title":"Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-alpha Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy","volume":"77","author":"Fend","year":"2017","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.04.008","article-title":"Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition","volume":"27","author":"Jennings","year":"2019","journal-title":"Mol Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/mto.2016.1","article-title":"Oncolytic vesicular stomatitis virus expressing interferon-gamma has enhanced therapeutic activity","volume":"3","author":"Bourgeois-Daigneault","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12985-024-02503-x","article-title":"The RNA-binding proteins regulate innate antiviral immune signaling by modulating pattern recognition receptors","volume":"21","author":"Li","year":"2024","journal-title":"Virol J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/v10020090","article-title":"Oncotargeting by vesicular stomatitis virus (VSV): advances in cancer therapy","volume":"10","author":"Bishnoi","year":"2018","journal-title":"Viruses"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/v17010016","article-title":"Employing the Oncolytic Vesicular Stomatitis Virus in Cancer Virotherapy: Resistance and Clinical Considerations","volume":"17","author":"Abdelmageed","year":"2024","journal-title":"Viruses"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0258224","DOI":"10.1128\/mbio.02582-24","article-title":"Interference without interferon: interferon-independent induction of interferon-stimulated genes and its role in cellular innate immunity","volume":"15","author":"Swaraj","year":"2024","journal-title":"mBio"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3365","article-title":"Mutations in the IFNgamma-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment","volume":"27","author":"Nguyen","year":"","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.898631","article-title":"Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.509","article-title":"Presence of the coxsackievirus and adenovirus receptor (CAR) in human neoplasms: a multitumour array analysis","volume":"109","author":"Reeh","year":"2013","journal-title":"Br J Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00351-3","article-title":"Cutting both ways: the innate immune response to oncolytic virotherapy","volume":"29","author":"Mealiea","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0599","article-title":"Oncolytic virotherapy blockade by microglia and macrophages requires STAT1\/3","volume":"78","author":"Delwar","year":"2018","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1141034","article-title":"Immunosuppressive cells in oncolytic virotherapy for glioma: challenges and solutions","volume":"13","author":"Liu","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1901234","article-title":"Activation of dendritic cells alters the mechanism of MHC Class II antigen presentation to CD4 T Cells","volume":"204","author":"Cho","year":"2020","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12935-024-03424-z","article-title":"Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments","volume":"24","author":"Yan","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B41","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41392-024-01824-1","article-title":"Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects","volume":"9","author":"Fu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcz162","article-title":"Immunosuppressive B cells expressing PD-1\/PD-L1 in solid tumors: a mini review","volume":"115","author":"Sun","year":"2022","journal-title":"QJM"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.11.010","article-title":"Modulating the tumor microenvironment via oncolytic viruses and csf-1r inhibition synergistically enhances anti-PD-1immunotherapy","volume":"27","author":"Shi","year":"2019","journal-title":"Mol Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","article-title":"Cholesterol induces CD8(+) T Cell exhaustion in the tumor microenvironment","volume":"30","author":"Ma","year":"2019","journal-title":"Cell Metab"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15825","article-title":"Neuropilin-1 is up-regulated by cancer-associated fibroblast-secreted IL-8 and associated with cell proliferation of gallbladder cancer","volume":"24","author":"Chen","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13027-025-00667-x","article-title":"DC-SIGN (CD209)-mediated interactions between bacteria, lung cancer tissues, and macrophages promote cancer metastasis","volume":"20","author":"Li","year":"2025","journal-title":"Infect Agent Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/path.5185","article-title":"Tumor and endothelial cells collaborate via transcellular receptor complexes","volume":"247","author":"Sarabipour","year":"2019","journal-title":"J Pathol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01236","article-title":"Oncoviruses Can Drive Cancer by Rewiring Signaling Pathways Through Interface Mimicry","volume":"9","author":"Guven-Maiorov","year":"2019","journal-title":"Front Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1088455","article-title":"p53 mutation and deletion contribute to tumor immune evasion","volume":"14","author":"Liu","year":"2023","journal-title":"Front Genet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","article-title":"Targeting mutant p53 for cancer therapy: direct and indirect strategies","volume":"14","author":"Hu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0064-6","article-title":"Molecular mechanisms of viral oncogenesis in humans","volume":"16","author":"Krump","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25116188","article-title":"The crucial role of inflammation and the immune system in colorectal cancer carcinogenesis: a comprehensive perspective","volume":"25","author":"Burgos-Molina","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae109","article-title":"Expression and prognostic relevance of PD-1, PD-L1, and CTLA-4 immune checkpoints in adrenocortical carcinoma","volume":"109","author":"Landwehr","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00940","article-title":"The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses","volume":"11","author":"Labani-Motlagh","year":"2020","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1287459","article-title":"Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target","volume":"15","author":"Hartupee","year":"2024","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01030","article-title":"Regulation of MAVS Expression and signaling function in the antiviral innate immune response","volume":"11","author":"Ren","year":"2020","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01167-5","article-title":"The role of plasmacytoid dendritic cells (pDCs) in immunity during viral infections and beyond","volume":"21","author":"Ngo","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01222","article-title":"What Makes a pDC: Recent Advances in Understanding Plasmacytoid DC Development and Heterogeneity","volume":"10","author":"Musumeci","year":"2019","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.749190","article-title":"The role of plasmacytoid dendritic cells in cancers","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: a review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00558-3","article-title":"Natural killer cells in antiviral immunity","volume":"22","author":"Bjorkstrom","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00174","article-title":"Neutrophils and macrophages: the main partners of phagocyte cell systems","volume":"3","author":"Silva","year":"2012","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e52991","DOI":"10.7759\/cureus.52991","article-title":"Complements and their role in systemic disorders","volume":"16","author":"Wang","year":"2024","journal-title":"Cureus"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.837767","article-title":"Cross Talk Between Natural Killer T and Dendritic Cells and Its Impact on T Cell Responses in Infections","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(01)00154-6","article-title":"Interferons alpha and beta as immune regulators\u2013a new look","volume":"14","author":"Biron","year":"2001","journal-title":"Immunity"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02057","article-title":"Antigenic Variability","volume":"11","author":"Mosa","year":"2020","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12943-025-02233-w","article-title":"Extracellular vesicles in tumor immunity: mechanisms and novel insights","volume":"24","author":"Kuang","year":"2025","journal-title":"Mol Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e143296","DOI":"10.1172\/JCI143296","article-title":"Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response","volume":"131","author":"von Locquenghien","year":"2021","journal-title":"J Clin Invest"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e1006989","DOI":"10.1371\/journal.ppat.1006989","article-title":"A novel mechanism of RNase L inhibition: Theiler's virus L* protein prevents 2-5A from binding to RNase L","volume":"14","author":"Drappier","year":"2018","journal-title":"PloS Pathog"},{"key":"B74","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13578-023-01073-9","article-title":"Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms","volume":"13","author":"Wang","year":"2023","journal-title":"Cell Biosci"},{"key":"B75","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12964-023-01244-8","article-title":"Regulation and clinical potential of telomerase reverse transcriptase (TERT\/hTERT) in breast cancer","volume":"21","author":"Yang","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B76","doi-asserted-by":"publisher","first-page":"jcs257188","DOI":"10.1242\/jcs.257188","article-title":"Ribosome quality control activity potentiates vaccinia virus protein synthesis during infection","volume":"134","author":"Sundaramoorthy","year":"2021","journal-title":"J Cell Sci"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e1515","DOI":"10.1002\/wrna.1515","article-title":"Translational control during poxvirus infection","volume":"10","author":"Meade","year":"2019","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e0263707","DOI":"10.1371\/journal.pone.0263707","article-title":"Optimizing environmental safety and cell-killing potential of oncolytic Newcastle Disease virus with modifications of the V, F and HN genes","volume":"17","author":"de Graaf","year":"2022","journal-title":"PloS One"},{"key":"B79","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","article-title":"Engineering strategies to enhance oncolytic viruses in cancer immunotherapy","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.200937","article-title":"Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma","volume":"33","author":"Watters","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2024.123595","article-title":"Herpes Simplex Oncolytic Viral Therapy for Malignant Glioma and Mechanisms of Delivery","volume":"194","author":"Erickson","year":"2025","journal-title":"World Neurosurg"},{"key":"B82","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/OV.S176523","article-title":"Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes","volume":"8","author":"Zainutdinov","year":"2019","journal-title":"Oncolytic Virother"},{"key":"B83","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s12935-022-02774-w","article-title":"Modifying oncolytic virotherapy to overcome the barrier of the hypoxic tumor microenvironment","volume":"22","author":"Shayan","year":"2022","journal-title":"Where do we stand? Cancer Cell Int"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41587-024-02467-x","article-title":"Directed evolution of engineered virus-like particles with improved production and transduction efficiencies","author":"Raguram","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.omto.2017.03.003","article-title":"Preclinical safety studies of enadenotucirev, a chimeric group b human-specific oncolytic adenovirus","volume":"5","author":"Illingworth","year":"2017","journal-title":"Mol Ther Oncolytics"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/v10080421","article-title":"Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection","volume":"10","author":"Bourhill","year":"2018","journal-title":"Viruses"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01163-20","article-title":"Reovirus sigma1 Conformational Flexibility Modulates the Efficiency of Host Cell Attachment","volume":"94","author":"Diller","year":"2020","journal-title":"J Virol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2014.11.002","article-title":"Amino acids substitutions in sigma1 and mu1 outer capsid proteins of a Vero cell-adapted mammalian orthoreovirus are required for optimal virus binding and disassembly","volume":"196","author":"Sandekian","year":"2015","journal-title":"Virus Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00941","article-title":"Alpha-Herpesvirus Thymidine Kinase Genes Mediate Viral Virulence and Are Potential Therapeutic Targets","volume":"10","author":"Xie","year":"2019","journal-title":"Front Microbiol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2004.11.012","article-title":"Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity","volume":"6","author":"O'Shea","year":"2004","journal-title":"Cancer Cell"},{"key":"B91","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.omto.2023.02.009","article-title":"Multi-modal efficacy of a chimeric vesiculovirus expressing the Morreton glycoprotein in sarcoma","volume":"29","author":"Watters","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.000980","article-title":"Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update","volume":"98","author":"Felt","year":"2017","journal-title":"J Gen Virol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/srep34531","article-title":"Increasing the Efficiency of CRISPR\/Cas9-mediated Precise Genome Editing of HSV-1 Virus in Human Cells","volume":"6","author":"Lin","year":"2016","journal-title":"Sci Rep"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2022.2112952","article-title":"An overview: CRISPR\/Cas-based gene editing for viral vaccine development","volume":"21","author":"Bhujbal","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/s41419-020-03285-0","volume":"11","author":"Liu","year":"2020","journal-title":"al.Intravenous injection oncolytic Virus M1 awakens antitumor T Cells overcomes resistance to checkpoint blockade. Cell Death Dis"},{"key":"B96","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12916-023-02901-y","article-title":"A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy","volume":"21","author":"Bahreyni","year":"2023","journal-title":"BMC Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.01.005","article-title":"A triple-regulated oncolytic adenovirus carrying microrna-143 exhibits potent antitumor efficacy in colorectal cancer","volume":"16","author":"Luo","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14652","article-title":"Development of an oncolytic recombinant vesicular stomatitis virus encoding a tumor-suppressor microRNA","volume":"40","author":"Sakuda","year":"2020","journal-title":"Anticancer Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.13188\/2381-3326.1000007","article-title":"A Novel Oncolytic Herpes Simplex Virus Design based on the Common Overexpression of microRNA-21 in Tumors","volume":"3","author":"Marzulli","year":"2018","journal-title":"J Gene Ther"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133233","article-title":"Inhibition of miR-222 by oncolytic adenovirus-encoded miRNA sponges promotes viral oncolysis and elicits antitumor effects in pancreatic cancer models","volume":"13","author":"Raimondi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.605380","article-title":"Strategies for targeting gene therapy in cancer cells with tumor-specific promoters","volume":"10","author":"Montano-Samaniego","year":"2020","journal-title":"Front Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12071596","article-title":"Enhancing neoadjuvant virotherapy's effectiveness by targeting stroma to improve resectability in pancreatic cancer","volume":"12","author":"Ferdous","year":"2024","journal-title":"Biomedicines"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8340","article-title":"Nectin-1 and HVEM: cellular receptors for HSV-1 in skin","volume":"7","author":"Knebel-Morsdorf","year":"2016","journal-title":"Oncotarget"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.2217\/fvl.15.85","article-title":"Cell entry mechanisms of HSV: what we have learned in recent years","volume":"10","author":"Agelidis","year":"2015","journal-title":"Future Virol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.2174\/1568009617666170222125035","article-title":"Clinical trials with oncolytic measles virus: current status and future prospects","volume":"18","author":"Msaouel","year":"2018","journal-title":"Curr Cancer Drug Targets"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00127","article-title":"Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective","volume":"7","author":"Kleinlutzum","year":"2017","journal-title":"Front Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00409-2","article-title":"Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411(NTR) leading to therapeutic benefit","volume":"29","author":"Singleton","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051070","article-title":"Novel Oncolytic Virus Armed with Cancer Suicide Gene and Normal Vasculogenic Gene for Improved Anti-Tumor Activity","volume":"12","author":"Jeong","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1186\/s41231-023-00144-w","article-title":"Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health","volume":"8","author":"Thoidingjam","year":"2023","journal-title":"Transl Med Commun"},{"key":"B110","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12672-025-01884-x","article-title":"Genetic advancements in breast cancer treatment: a review","volume":"16","author":"Shokoohi","year":"2025","journal-title":"Discovery Oncol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12943-024-02193-7","article-title":"Metabolic targeting of regulatory T cells in oral squamous cell carcinoma: new horizons in immunotherapy","volume":"23","author":"Gan","year":"2024","journal-title":"Mol Cancer"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-023-04669-4","article-title":"Reprogramming of glucose metabolism in virus infected cells","volume":"478","author":"Goyal","year":"2023","journal-title":"Mol Cell Biochem"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1142172","article-title":"Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response","volume":"13","author":"Wu","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00262-024-03757-8","article-title":"Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy","volume":"73","author":"Zhang","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0828-7","article-title":"Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma","volume":"34","author":"Packiriswamy","year":"2020","journal-title":"Leukemia"},{"key":"B116","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-024-01554-5","article-title":"Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening","volume":"17","author":"Zhong","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0285","article-title":"Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus","volume":"23","author":"Eriksson","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B118","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/gt.2016.80","article-title":"Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment","volume":"24","author":"Eriksson","year":"2017","journal-title":"Gene Ther"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.02.006","article-title":"Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform","volume":"20","author":"Ylosmaki","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-020-0176-9","article-title":"Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and\/or CD40","volume":"27","author":"Wenthe","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1375433","article-title":"New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy","volume":"15","author":"Chowaniec","year":"2024","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123650","article-title":"TGF-beta mediated immune evasion in cancer-spotlight on cancer-associated fibroblasts","volume":"12","author":"Ghahremanifard","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-023-00720-0","article-title":"BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors","volume":"31","author":"Conley","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0481","article-title":"BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors","volume":"18","author":"Kesari","year":"2022","journal-title":"Future Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800717","article-title":"IL-6 signaling blockade during CD40-mediated immune activation favors antitumor factors by reducing TGF-beta, collagen Type I, and PD-L1\/PD-1","volume":"202","author":"Eriksson","year":"2019","journal-title":"J Immunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"e20230053","DOI":"10.1084\/jem.20230053","article-title":"An oncolytic virus-delivered TGFbeta inhibitor overcomes the immunosuppressive tumor microenvironment","volume":"220","author":"DePeaux","year":"2023","journal-title":"J Exp Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.240","article-title":"T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy","volume":"22","author":"Yu","year":"2014","journal-title":"Mol Ther"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12121309","article-title":"4-1BBL-Armed Oncolytic Herpes Simplex Virus Exerts Antitumor Effects in Pancreatic Ductal Adenocarcinoma","volume":"12","author":"Gao","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1423143","article-title":"The investigation of oncolytic viruses in the field of cancer therapy","volume":"14","author":"Yuan","year":"2024","journal-title":"Front Oncol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bbrep.2017.12.004","article-title":"Measles virus: Background and oncolytic virotherapy","volume":"13","author":"Bhattacharjee","year":"2018","journal-title":"Biochem Biophys Rep"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2013.84","article-title":"In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models","volume":"21","author":"Jing","year":"2014","journal-title":"Gene Ther"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.831091","article-title":"Genetic Modifications That Expand Oncolytic Virus Potency","author":"Cristi","year":"2022","journal-title":"Front Mol Biosci 9"},{"key":"B133","doi-asserted-by":"publisher","first-page":"e008431","DOI":"10.1136\/jitc-2023-008431","article-title":"An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy","volume":"12","author":"Wang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01168-10","article-title":"Small peptide inhibitors disrupt a high-affinity interaction between cytoplasmic dynein and a viral cargo protein","volume":"84","author":"Hernaez","year":"2010","journal-title":"J Virol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"e81606","DOI":"10.7554\/eLife.81606","article-title":"Antiviral function and viral antagonism of the rapidly evolving dynein activating adaptor NINL","volume":"11","author":"Stevens","year":"2022","journal-title":"Elife"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.575992","article-title":"Tumor treating fields: at the crossroads between physics and biology for cancer treatment","volume":"10","author":"Carrieri","year":"2020","journal-title":"Front Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01848","article-title":"Immune conversion of tumor microenvironment by oncolytic viruses: the protoparvovirus H-1PV case study","volume":"10","author":"Marchini","year":"2019","journal-title":"Front Immunol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12094-024-03551-z","article-title":"Tumor-treating fields in cancer therapy: advances of cellular and molecular mechanisms","volume":"27","author":"Xiao","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0603","article-title":"Integration of tumor-treating fields into the multidisciplinary management of patients with solid malignancies","volume":"24","author":"Wang","year":"2019","journal-title":"Oncologist"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3232","article-title":"Phase i trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma","volume":"23","author":"Mell","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyaa247","article-title":"From Bench to Bedside, the Current State of Oncolytic Virotherapy in Pediatric Glioma","volume":"87","author":"Soldozy","year":"2020","journal-title":"Neurosurgery"},{"key":"B142","doi-asserted-by":"publisher","first-page":"e006780","DOI":"10.1136\/jitc-2023-006780","article-title":"Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer","volume":"11","author":"Jhawar","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B143","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.09.040","article-title":"Stereotactic body radiation combined with oncolytic vaccinia virus induces potent anti-tumor effect by triggering tumor cell necroptosis and DAMPs","volume":"523","author":"Chen","year":"2021","journal-title":"Cancer Lett"},{"key":"B145","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40478-019-0714-6","article-title":"Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models","volume":"7","author":"Martinez-Velez","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3390\/cells13171500","article-title":"PI3K\/AKT\/mTOR Signaling Network in Human Health and Diseases","volume":"13","author":"Omolekan","year":"2024","journal-title":"Cells"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3390\/cells12121671","article-title":"The PI3K-Akt-mTOR and associated signaling pathways as molecular drivers of immune-mediated inflammatory skin diseases: update on therapeutic strategy using natural and synthetic compounds","volume":"12","author":"Roy","year":"2023","journal-title":"Cells"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080803","article-title":"Role and therapeutic targeting of the PI3K\/Akt\/mTOR signaling pathway in skin cancer: a review of current status and future trends on natural and synthetic agents therapy","volume":"8","author":"Chamcheu","year":"2019","journal-title":"Cells"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1972802","article-title":"Advances in viral oncolytics for treatment of multiple myeloma - a focused review","volume":"14","author":"Sarwar","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3892\/or.2014.3020","article-title":"PI3K inhibitor LY294002 inhibits activation of the Akt\/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus","volume":"31","author":"Tong","year":"2014","journal-title":"Oncol Rep"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01359-20","article-title":"Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model","volume":"95","author":"Uche","year":"2021","journal-title":"J Virol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-018-0011-8","article-title":"Synergistic antitumour effects of rapamycin and oncolytic reovirus","volume":"25","author":"Comins","year":"2018","journal-title":"Cancer Gene Ther"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040614","article-title":"Personalizing oncolytic virotherapy for glioblastoma: in search of biomarkers for response","volume":"13","author":"Stavrakaki","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27955","article-title":"Transforming growth factor-beta signaling: Tumorigenesis and targeting for cancer therapy","volume":"234","author":"Ahmadi","year":"2019","journal-title":"J Cell Physiol"},{"key":"B155","article-title":"Oncolytic newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells","volume":"8","author":"Ye","year":"2018","journal-title":"Am J Cancer Res"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-551","article-title":"Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells","volume":"14","author":"Jiang","year":"2014","journal-title":"BMC Cancer"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1007\/s10565-019-09502-7","article-title":"Temozolomide induces activation of Wnt\/beta-catenin signaling in glioma cells via PI3K\/Akt pathway: implications in glioma therapy","volume":"36","author":"Tomar","year":"2020","journal-title":"Cell Biol Toxicol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"e000345","DOI":"10.1136\/jitc-2019-000345","article-title":"Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma","volume":"8","author":"Saha","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B159","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41392-021-00609-0","article-title":"Modulating the tumor microenvironment via oncolytic virus and PI3K inhibition synergistically restores immune checkpoint therapy response in PTEN-deficient glioblastoma","volume":"6","author":"Xing","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B160","doi-asserted-by":"publisher","first-page":"e001624","DOI":"10.1136\/jitc-2020-001624","article-title":"A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer","volume":"9","author":"Marelli","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B161","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","article-title":"mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges","volume":"10","author":"Zou","year":"2020","journal-title":"Cell Biosci"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15564","article-title":"Safety and efficacy of RAD001 (Everolimus) administered upon relapse during or after adjuvant treatment in post-menopausal women with hormone receptor positive, her2\/neu negative locally advanced or metastatic breast cancer (CRAD001JGR08 \"MELPOMENI\" study)","volume":"42","author":"Alexopoulos","year":"2022","journal-title":"Anticancer Res"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010171","article-title":"Oncolytic virotherapy with myxoma virus","volume":"9","author":"Rahman","year":"2020","journal-title":"J Clin Med"},{"key":"B164","doi-asserted-by":"publisher","first-page":"e1007264","DOI":"10.1371\/journal.ppat.1007264","article-title":"Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E\/4E-BP axis","volume":"14","author":"Zakaria","year":"2018","journal-title":"PloS Pathog"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3390\/cells9102297","article-title":"Role of the JAK\/STAT pathway in cervical cancer: its relationship with HPV E6\/E7 oncoproteins","volume":"9","author":"Gutierrez-Hoya","year":"2020","journal-title":"Cells"},{"key":"B166","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.clim.2016.09.014","article-title":"Role of the JAK\/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases","volume":"189","author":"Yan","year":"2018","journal-title":"Clin Immunol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-018-0074-6","article-title":"JAK\/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models","volume":"26","author":"Patel","year":"2019","journal-title":"Cancer Gene Ther"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2015.08.003","article-title":"Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1","volume":"485","author":"Cataldi","year":"2015","journal-title":"Virology"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-15-0427","article-title":"STAT1 and NF-kappaB inhibitors diminish basal interferon-stimulated gene expression and improve the productive infection of oncolytic HSV in MPNST Cells","volume":"14","author":"Jackson","year":"2016","journal-title":"Mol Cancer Res"},{"key":"B170","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12964-023-01240-y","article-title":"Double-edged sword of JAK\/STAT signaling pathway in viral infections: novel insights into virotherapy","volume":"21","author":"Mahjoor","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.630678","article-title":"SP600125, a JNK-specific inhibitor, regulates in vitro auricular cartilage regeneration by promoting cell proliferation and inhibiting extracellular matrix metabolism","volume":"9","author":"Zhang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41580-019-0110-x","article-title":"The multiple mechanisms that regulate p53 activity and cell fate","volume":"20","author":"Hafner","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1186\/s12935-021-02396-8","article-title":"p53 signaling in cancer progression and therapy","volume":"21","author":"Marei","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252312990","article-title":"The potential of oncolytic virotherapy in the treatment of head and neck cancer: a comprehensive review","volume":"25","author":"Spirito","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B175","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-022-01314-3","article-title":"Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials","volume":"15","author":"Zhu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12935-024-03356-8","article-title":"MDM2: current research status and prospects of tumor treatment","volume":"24","author":"Yao","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer","author":"Du","year":"2018","journal-title":"Mol Cancer 17"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2019.04.004","article-title":"Combination of cetuximab and oncolytic virus canerpaturev synergistically inhibits human colorectal cancer growth","volume":"13","author":"Wu","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00479","article-title":"Comparative efficacy, safety, and costs of sorafenib vs. sunitinib as first-line therapy for metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"9","author":"Deng","year":"2019","journal-title":"Front Oncol"},{"key":"B181","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12943-022-01664-z","article-title":"Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol Cancer"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0143","article-title":"Repurposing sunitinib with oncolytic reovirus as a novel immunotherapeutic strategy for renal cell carcinoma","volume":"22","author":"Lawson","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-3308","article-title":"Amplification of oncolytic vaccinia virus widespread tumor cell killing by sunitinib through multiple mechanisms","volume":"78","author":"Kim","year":"2018","journal-title":"Cancer Res"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1615817","article-title":"Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)","volume":"8","author":"Moehler","year":"2019","journal-title":"Oncoimmunology"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1159\/000533650","article-title":"PHOCUS: a phase 3, randomized, open-label study of sequential treatment with pexa-vec (JX-594) and sorafenib in patients with advanced hepatocellular carcinoma","volume":"13","author":"Abou-Alfa","year":"2024","journal-title":"Liver Cancer"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0591","article-title":"CSF1\/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates t-cell infiltration in the sarcoma microenvironment","volume":"20","author":"Fujiwara","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12820","article-title":"Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1","volume":"14","author":"Cai","year":"2020","journal-title":"Mol Oncol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.15","article-title":"BRAF- and MEK-targeted small molecule inhibitors exert enhanced antimelanoma effects in combination with oncolytic reovirus through er stress","author":"Roulstone","year":"2015","journal-title":"Mol Ther 23"},{"key":"B189","doi-asserted-by":"publisher","first-page":"eaau0417","DOI":"10.1126\/scitranslmed.aau0417","article-title":"MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation","volume":"10","author":"Bommareddy","year":"2018","journal-title":"Sci Transl Med"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.04.006","article-title":"Inhibition of MEK-ERK pathway enhances oncolytic vaccinia virus replication in doxorubicin-resistant ovarian cancer","volume":"25","author":"Lee","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B191","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s40425-019-0667-0","article-title":"Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape","volume":"7","author":"Osipov","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143386","article-title":"Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits","volume":"13","author":"Spiesschaert","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.3390\/v12121356","article-title":"Valproic Acid and Its Amidic Derivatives as New Antivirals against Alphaherpesviruses","volume":"12","author":"Andreu","year":"2020","journal-title":"Viruses"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-383","article-title":"Cell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erk1\/2 phosphorylation","volume":"10","author":"Gotfryd","year":"2010","journal-title":"BMC Cancer"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.02.156","article-title":"Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor","volume":"356","author":"Roskoski","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17173","article-title":"Oncolytic herpes simplex virus type 1 (HSV-1) in combination with lenalidomide for plasma cell neoplasms","volume":"192","author":"Oku","year":"2021","journal-title":"Br J Haematol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-567958","article-title":"The novel mechanism of lenalidomide activity","volume":"126","author":"Fink","year":"2015","journal-title":"Blood"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-278432","article-title":"The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy","volume":"117","author":"Hsu","year":"2011","journal-title":"Blood"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-578286","article-title":"How does lenalidomide target the chronic lymphocytic leukemia microenvironment","volume":"124","author":"Kater","year":"2014","journal-title":"Blood"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"B201","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/OV.S136644","article-title":"Potential of oncolytic viruses in the treatment of multiple myeloma","volume":"7","author":"Bartee","year":"2017","journal-title":"Oncolytic Virother"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.03.024","article-title":"Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program","volume":"33","author":"Lane","year":"2006","journal-title":"Semin Oncol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.05.026","article-title":"Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway","volume":"61","author":"Zhou","year":"2014","journal-title":"J Hepatol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/413076","article-title":"Paclitaxel and its evolving role in the management of ovarian cancer","volume":"2015","author":"Kampan","year":"2015","journal-title":"BioMed Res Int"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.66","article-title":"Randomized phase 2 trial of the oncolytic virus pelareorep (reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma","volume":"24","author":"Noonan","year":"2016","journal-title":"Mol Ther"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11092359","article-title":"A comprehensive review of natural products as therapeutic or chemopreventive agents against head and neck squamous cell carcinoma cells using preclinical models","volume":"11","author":"Liew","year":"2023","journal-title":"Biomedicines"},{"key":"B207","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-016-3003-0","article-title":"Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective","volume":"78","author":"Ciccolini","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14082022","article-title":"Combination of LIGHT (TNFSF14)-Armed Myxoma Virus Pre-Loaded into ADSCs and Gemcitabine in the Treatment of Experimental Orthotopic Murine Pancreatic Adenocarcinoma","volume":"14","author":"Jazowiecka-Rakus","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01300","article-title":"Evolution of cancer pharmacological treatments at the turn of the third millennium","volume":"9","author":"Falzone","year":"2018","journal-title":"Front Pharmacol"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800991","article-title":"The next generation of immunotherapy for cancer: small molecules could make big waves","volume":"202","author":"Kerr","year":"2019","journal-title":"J Immunol"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-020-03599-4","article-title":"Regulation of histone deacetylase activities and functions by phosphorylation and its physiological relevance","volume":"78","author":"Bahl","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"B212","doi-asserted-by":"publisher","first-page":"e1006799","DOI":"10.1371\/journal.ppat.1006799","article-title":"HDAC6 controls innate immune and autophagy responses to TLR-mediated signalling by the intracellular bacteria Listeria monocytogenes","volume":"13","author":"Moreno-Gonzalo","year":"2017","journal-title":"PloS Pathog"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-021-00215-x","article-title":"Transcriptional analysis of sodium valproate in a serotonergic cell line reveals gene regulation through both HDAC inhibition-dependent and independent mechanisms","volume":"21","author":"Sinha","year":"2021","journal-title":"Pharmacogenomics J"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.3390\/v11060562","article-title":"H-1 parvovirus as a cancer-killing agent: past, present, and future","volume":"11","author":"Bretscher","year":"2019","journal-title":"Viruses"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00626-19","article-title":"SIRT1 modulates the sensitivity of prostate cancer cells to vesicular stomatitis virus oncolysis","volume":"93","author":"Muscolini","year":"2019","journal-title":"J Virol"},{"key":"B216","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40169-018-0214-5","article-title":"Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials","volume":"7","author":"LaRocca","year":"2018","journal-title":"Clin Transl Med"},{"key":"B217","doi-asserted-by":"publisher","first-page":"e001701","DOI":"10.1136\/jitc-2020-001701","article-title":"Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany","volume":"9","author":"Ressler","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12031098","article-title":"Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy","volume":"12","author":"Zhang","year":"2023","journal-title":"J Clin Med"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"B220","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy","volume":"4","author":"Rehman","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J Clin Oncol"},{"key":"B222","doi-asserted-by":"publisher","first-page":"e006270","DOI":"10.1136\/jitc-2022-006270","article-title":"Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial","volume":"11","author":"Chesney","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01670-w","article-title":"Cancer vaccines: current status and future directions","volume":"18","author":"Zhou","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02846-x","article-title":"Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages","volume":"23","author":"Dong","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13947","article-title":"Recombinant human adenovirus type 5 (Oncorine) reverses resistance to immune checkpoint inhibitor in a patient with recurrent non-small cell lung cancer: A case report","volume":"12","author":"Zhang","year":"2021","journal-title":"Thorac Cancer"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1042250","article-title":"Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.3390\/v15020367","article-title":"Inactivation of the UL37 Deamidase Enhances Virus Replication and Spread of the HSV-1(VC2) Oncolytic Vaccine Strain and Secretion of GM-CSF","volume":"15","author":"Clark","year":"2023","journal-title":"Viruses"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1199068","article-title":"The Oncolytic herpes simplex virus type-1 (HSV-1) vaccine strain VC2 causes intratumor infiltration of functionally active T cells and inhibition of tumor metastasis and pro-tumor genes VEGF and PDL1 expression in the 4T1\/Balb\/c mouse model of stage four breast cancer","volume":"10","author":"Nabi","year":"2023","journal-title":"Front Mol Biosci"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1007\/s40588-015-0020-4","article-title":"Herpes simplex vaccines: prospects of live-attenuated hsv vaccines to combat genital and ocular infections","volume":"2","author":"Stanfield","year":"2015","journal-title":"Curr Clin Microbiol Rep"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25126733","article-title":"Recurrent glioblastoma-molecular underpinnings and evolving treatment paradigms","volume":"25","author":"Chang","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2900","article-title":"Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients","volume":"23","author":"Streby","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.120","article-title":"Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma","volume":"31","author":"Dispenzieri","year":"2017","journal-title":"Leukemia"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.688755","article-title":"Repurposing Infectious Diseases Vaccines Against Cancer","volume":"11","author":"Vandeborne","year":"2021","journal-title":"Front Oncol"},{"key":"B234","doi-asserted-by":"publisher","first-page":"e008880","DOI":"10.1136\/jitc-2024-008880","article-title":"Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival","volume":"12","author":"Bommareddy","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.101","article-title":"Phase 1 study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers","volume":"24","author":"Downs-Canner","year":"2016","journal-title":"Mol Ther"},{"key":"B236","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.omto.2022.03.003","article-title":"Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response","volume":"25","author":"Zhang","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1206111","article-title":"Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells","volume":"13","author":"Kardani","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae1103","article-title":"Retargeting target-directed microRNA-decay sites to highly expressed viral or cellular miRNAs","volume":"52","author":"Ortega","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29856","article-title":"Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors","volume":"122","author":"Villalona-Calero","year":"2016","journal-title":"Cancer"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1003","article-title":"Bortezomib treatment sensitizes oncolytic HSV-1-treated tumors to nk cell immunotherapy","volume":"22","author":"Yoo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1535647","article-title":"Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses","volume":"15","author":"Soko","year":"2024","journal-title":"Front Immunol"},{"key":"B242","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","article-title":"Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection","volume":"5","author":"Garcia-Carbonero","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32325","article-title":"Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment","volume":"145","author":"Koske","year":"2019","journal-title":"Int J Cancer"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol Cancer"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2023.0202","article-title":"Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review","volume":"20","author":"Li","year":"2023","journal-title":"Cancer Biol Med"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.789454","article-title":"Intramuscular vaccination with the HSV-1(VC2) live-attenuated vaccine strain confers protection against viral ocular immunopathogenesis associated with gammadeltaT cell intracorneal infiltration","volume":"12","author":"Nabi","year":"2021","journal-title":"Front Immunol"},{"key":"B247","volume-title":"A Comprehensive Guide to Toxicology in Nonclinical Drug Development (Second Edition)","author":"Ali Said","year":"2017"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat5025","article-title":"Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade","volume":"11","author":"Shekarian","year":"2019","journal-title":"Sci Transl Med"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314710","article-title":"The impact of curcumin on immune response: an immunomodulatory strategy to treat sepsis","volume":"23","author":"Allegra","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B250","doi-asserted-by":"publisher","first-page":"10696","DOI":"10.1038\/s41598-024-61662-7","article-title":"Antiviral, anti-inflammatory and antioxidant effects of curcumin and curcuminoids in SH-SY5Y cells infected by SARS-CoV-2","volume":"14","author":"Nicoliche","year":"2024","journal-title":"Sci Rep"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28122","article-title":"Mechanisms of apoptosis modulation by curcumin: Implications for cancer therapy","volume":"234","author":"Mortezaee","year":"2019","journal-title":"J Cell Physiol"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10091440","article-title":"Resveratrol as an Adjunctive Therapy for Excessive Oxidative Stress in Aging COVID-19 Patients","volume":"10","author":"Liao","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061642","article-title":"VEGF upregulation in viral infections and its possible therapeutic implications","volume":"19","author":"Alkharsah","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231182362","article-title":"Safety and efficacy of Vitamin C, Vitamin E, and selenium supplementation in the oncology setting: A systematic review","volume":"30","author":"Barnhart","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"B255","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1038\/s41598-018-20213-7","article-title":"Synergistic Anti-tumour Effects of Quercetin and Oncolytic Adenovirus expressing TRAIL in Human Hepatocellular Carcinoma","volume":"8","author":"Zou","year":"2018","journal-title":"Sci Rep"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-020-04706-3","article-title":"Antiviral activity of berberine","volume":"165","author":"Warowicka","year":"2020","journal-title":"Arch Virol"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00122","article-title":"The anti-inflammatory role of omega-3 polyunsaturated fatty acids metabolites in pre-clinical models of psychiatric, neurodegenerative, and neurological disorders","volume":"11","author":"Giacobbe","year":"2020","journal-title":"Front Psychiatry"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-015-9572-2","article-title":"Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials","volume":"34","author":"Nabavi","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3105","article-title":"A phase i trial of talimogene laherparepvec in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer","volume":"27","author":"Soliman","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B260","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13058-016-0744-y","article-title":"Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment","volume":"18","author":"Bourgeois-Daigneault","year":"2016","journal-title":"Breast Cancer Res"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.05.015","article-title":"Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment","volume":"283","author":"Garofalo","year":"2018","journal-title":"J Control Release"},{"key":"B262","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3892\/or.2018.6817","article-title":"Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer","volume":"41","author":"Chen","year":"2019","journal-title":"Oncol Rep"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.03.009","article-title":"Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer","volume":"396","author":"Jung","year":"2017","journal-title":"Cancer Lett"},{"key":"B264","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1186\/s12885-018-4453-z","article-title":"A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer","volume":"18","author":"Hirooka","year":"2018","journal-title":"BMC Cancer"},{"key":"B265","doi-asserted-by":"publisher","first-page":"e003255","DOI":"10.1136\/jitc-2021-003255","article-title":"multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors","volume":"10","author":"Garcia-Carbonero","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-10-293","article-title":"Combination of autophagy inducer rapamycin and oncolytic adenovirus improves antitumor effect in cancer cells","volume":"10","author":"Cheng","year":"2013","journal-title":"Virol J"},{"key":"B267","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/1078-0432.CCR-19-2078","article-title":"Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: a phase ib study","volume":"26","author":"Mahalingam","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S267383","article-title":"Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy","volume":"13","author":"Tchounwou","year":"2021","journal-title":"J Exp Pharmacol"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2017.08.002","article-title":"Myxoma virus optimizes cisplatin for the treatment of ovarian cancer in vitro and in a syngeneic murine dissemination model","volume":"6","author":"Nounamo","year":"2017","journal-title":"Mol Ther Oncolytics"},{"key":"B270","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.omto.2018.12.003","article-title":"Enhanced delivery of oncolytic adenovirus by neural stem cells for treatment of metastatic ovarian cancer","volume":"12","author":"Mooney","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01210-8","article-title":"Synergism of rMV-Hu191 with cisplatin to treat gastric cancer by acid sphingomyelinase-mediated apoptosis requiring integrity of lipid raft microdomains","volume":"24","author":"Lv","year":"2021","journal-title":"Gastric Cancer"},{"key":"B272","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.omto.2019.08.003","article-title":"Combination therapy with reovirus and ATM inhibitor enhances cell death and virus replication in canine melanoma","volume":"15","author":"Igase","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"B273","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1038\/s41598-022-07228-x","article-title":"PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma","volume":"12","author":"Davern","year":"2022","journal-title":"Sci Rep"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.7150\/jca.46868","article-title":"Combination of oncolytic adenovirus targeting SATB1 and docetaxel for the treatment of castration-resistant prostate cancer","volume":"12","author":"Mao","year":"2021","journal-title":"J Cancer"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13849","article-title":"Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model","volume":"8","author":"Dobson","year":"2017","journal-title":"Oncotarget"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01645-3","article-title":"Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects","volume":"18","author":"Dona","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B277","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2014-1709","article-title":"Reovirus synergy with proteosome inhibitor carfilzomib and Akt inhibitor perifisone overcomes therapy resistance of multiple myeloma: promising preclinical activity","volume":"74","author":"Thirukkumaran","year":"2014","journal-title":"Cancer Res"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0047","article-title":"Bortezomib induces anti-multiple myeloma immune response mediated by cGAS\/STING pathway activation","volume":"2","author":"Gulla","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"B279","doi-asserted-by":"publisher","first-page":"20200669","DOI":"10.1098\/rsif.2020.0669","article-title":"Polytherapeutic strategies with oncolytic virus-bortezomib and adjuvant NK cells in cancer treatment","volume":"18","author":"Aspirin","year":"2021","journal-title":"J R Soc Interface"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0553","article-title":"Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects","volume":"20","author":"Yoo","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B281","doi-asserted-by":"publisher","first-page":"e0127058","DOI":"10.1371\/journal.pone.0127058","article-title":"The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells","volume":"10","author":"Berghauser Pont","year":"2015","journal-title":"PloS One"},{"key":"B282","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/ITT.S273327","article-title":"Therapeutic Vaccines for HPV-Associated Malignancies","volume":"9","author":"Smalley Rumfield","year":"2020","journal-title":"Immunotargets Ther"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/124439","article-title":"Anticancer activity of topical ointments with histone deacetylase inhibitor, trichostatin A","volume":"29","author":"Chodkowska","year":"2020","journal-title":"Adv Clin Exp Med"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.58","article-title":"Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects","volume":"16","author":"Liu","year":"2008","journal-title":"Mol Ther"},{"key":"B285","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2008.81","article-title":"The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells","volume":"16","author":"Katsura","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1007\/s10577-024-09748-w","article-title":"Two decades of chromosomal instability and aneuploidy","volume":"32","author":"Santaguida","year":"2024","journal-title":"Chromosome Res"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112761","article-title":"Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives","volume":"13","author":"Chianese","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B288","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14040978","article-title":"Controlling cell trafficking: addressing failures in CAR T and NK cell therapy of solid tumours","volume":"14","author":"White","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discovery"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1618751\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T05:26:44Z","timestamp":1756099604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1618751\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":289,"alternative-id":["10.3389\/fimmu.2025.1618751"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1618751","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"article-number":"1618751"}}